1.
SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]
CA Cancer J Clin
.
.
2021;
71
(3):209–249. doi: 10.3322/caac.21660.
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
3.
RUIZ E M L, NIU T, ZERFAOUI M, et al. A novel gene panel for prediction of lymph-node metastasis and recurrence in patients with thyroid cancer[J]
Surgery
.
.
2020;
167
(1):73–79. doi: 10.1016/j.surg.2019.06.058.
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
4.
张丽林, 赵留芳, 李晓江. 复发转移性分化型甲状腺癌诊疗进展[J].
国际耳鼻咽喉头颈外科杂志
, 2018, 42(3): 149-153
ZHANG Lilin, ZHAO Liufang, LI Xiaojiang. Progress in diagnosis and treatment of recurrent or metastatic differentiated thyriod cancer[J].
International Journal of Otolaryngology-Head and Neck Surgery
, 2018, 42(3): 149-153. (in Chinese)
5.
林岩松, 张彬, 梁智勇, 等. 复发转移性分化型甲状腺癌诊治共识[J].
中国癌症杂志
, 2015, 25(7): 481-496
LIN Yansong, ZHANG Bin, LIANG Zhiyong, et al. Consensus on diagnosis and treatment of recurrent metastatic differentiated thyroid carcinoma[J].
China Oncology
, 2015, 25(7): 481-496. (in Chinese)
6.
中华医学会内分泌学分会, 中华医学会外科学分会内分泌学组, 中国抗癌协会头颈肿瘤专业委员会, 等.甲状腺结节和分化型甲状腺癌诊治指南[J].
中华核医学与分子影像杂志
, 2013, 33(2): 96-115
Chinese Society of Endocrinology, Chinese Society of Surgery of Chinese Medical Association Endocrinology Group, Chinese Association of Head and Neck Oncology, et al. Guidelines for the diagnosis and treatment of thyroid nodules and differentiated thyroid carcinoma[J].
Chinese Journal of Nuclear Medicine and Molecular Imaging
, 2013, 33(2): 96-115. (in Chinese)
7.
AMIN M B, GREENE F L, EDGE S B, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging[J]
CA-Cancer J Clin
.
.
2017;
67
(2):93–99. doi: 10.3322/caac.21388.
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
10.
LANG B H H, LO C Y, CHAN W F, et al. Prognostic factors in papillary and follicular thyroid carcinoma: their implications for cancer staging[J]
Ann Surg Oncol
.
.
2007;
14
(2):730–738. doi: 10.1245/s10434-006-9207-5.
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
11.
SHOKOOHI A, BERTHELET E, GILL S, et al. Treatment for recurrent differentiated thyroid cancer: a canadian population based experience[J/OL]
Cureus
.
.
2020;
12
(2):e7122. doi: 10.7759/cureus.7122.
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
12.
TAM S, BOONSRIPITAYANON M, AMIT M, et al. Survival in differentiated thyroid cancer: comparing the AJCC cancer staging seventh and eighth editions[J]
Thyroid
.
.
2018;
28
(10):1301–1310. doi: 10.1089/thy.2017.0572.
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
14.
DING J, WU W, FANG J, et al. Male sex is associated with aggressive behaviour and poor prognosis in Chinese papillary thyroid carcinoma[J]
Sci Rep
.
.
2020;
10
(1):4141. doi: 10.1038/s41598-020-60199-9.
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
15.
ZAHEDI A, BONDAZ L, RAJARAMAN M, et al. Risk for thyroid cancer recurrence is higher in men than in women independent of disease stage at presentation[J]
Thyroid
.
.
2020;
30
(6):871–877. doi: 10.1089/thy.2018.0775.
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
17.
黄璐, 李超, 王薇, 等.甲状腺癌腺外侵犯的意义及最新研究进展[J].
中华耳鼻咽喉头颈外科杂志
, 2019, 54(9): 717-720
[
PubMed
]
HUANG Lu, LI Chao, WANG Wei, et al. The significance and latest progress of extrathyroidal extension of thyroid cancer[J].
Chinese Journal of Otorhinolaryngology Head and Neck Surgery
, 2019, 54(9): 717-720. (in Chinese)
[
PubMed
]
18.
PARK J, KIM K, LIM D J, et al. Male sex is not an independent risk factor for recurrence of differentiated thyroid cancer: a propensity score-matching study[J]
Sci Rep
.
.
2021;
11
(1):14908. doi: 10.1038/s41598-021-94461-5.
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
19.
HAUGEN B R, ALEXANDER E K, BIBLE K C, et al. 2015 american thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]
Thyroid
.
.
2016;
26
(1):1–133. doi: 10.1089/thy.2015.0020.
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
20.
TIWARI Y, KRISHNAMURTHY A. Long-term outcomes of differentiated thyroid cancers with tracheal invasion: a 15-year experience[J]
Indian J Cancer
.
.
2020;
57
(4):398–404. doi: 10.4103/ijc.IJC_456_19.
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
21.
GRANI G, RAMUNDO V, VERRIENTI A, et al. Thyroid hormone therapy in differentiated thyroid cancer[J]
Endocrine
.
.
2019;
66
(1):43–50. doi: 10.1007/s12020-019-02051-3.
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
22.
TUTTLE R M, AHUJA S, AVRAM A M, et al. Controversies, consensus, and collaboration in the use of
131
I therapy in differentiated thyroid cancer: a joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association[J]
Thyroid
.
.
2019;
29
(4):461–470. doi: 10.1089/thy.2018.0597. [
PubMed
] [
CrossRef
]
[
Google Scholar
]
24.
SAMHOURI L, KRIZ J, ELSAYAD K, et al. The role of radiotherapy for patients with thyroid cancer in the modern era[J]
Anticancer Res
.
.
2020;
40
(6):3379–3386. doi: 10.21873/anticanres.14321.
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
